Clarient Acquires AGI In All-Stock Merger
Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.
Member Spotlight
Possible Cause of Inflammatory Bowel Disease Uncovered
A researcher at the University of Adelaide found that people suffering from inflammatory bowel disease have a lower number of regulatory cells that control the immune system.
Cytori’s (NASDAQ: CYTX) Natural Celution for Breast Reconstruction
Cytori Therapeutics is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types.
[Company Profile] Stentys
Medical device company Stentys seeks to correct the problem of poor apposition with its self-expanding stent technology.
CytRx to Initiate Clinical Trial for Soft Tissue Cancer Drug
CytRx, a biopharmaceutical research and development company, has announced plans to initiate a Phase II clinical trial for its drug candidate INNO-206 to treat patients who suffer from advanced, treatment-resistant soft tissue sarcoma.
Echo Therapeutics: Positive Developments for Needle-Free Monitoring System
On 11/19/09, the Company announced positive results in a pilot clinical study which included Prelude skin preparation and the placement of 10 Symphony tCGM biosensors on subjects with Type 1 or Type 2 Diabetes.
Interview with Jeffrey Davis, CEO of Access Pharmaceuticals
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company’s pipeline.
BioDelivery Sciences (NASDAQ: BDSI): Restarting the Catalyst Cycle
BDSI focuses on the niche market of pain management and supportive cancer care.
DATATRAK: Low Valuation, Improving Results
DATATRAK International Inc. (OTC: DATA.PK) is a clinical trials information technology (IT) and services company that is focused on increasing its share of an estimated $720 million (M) Electronic Data Capture (EDC) market opportunity.
Positive Phase II Data for Peregrine’s Lung Cancer Treatment
Peregrine Pharmaceuticals reported positive Phase II data in a clinical trial of bavituximab in patients with a deadly form of lung cancer.